Symbols / EVAX $3.86 +0.65%
EVAX Chart
About
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 32.15M |
| Enterprise Value | 1.58B | Income | -7.71M | Sales | 7.53M |
| Book/sh | 2.04 | Cash/sh | 0.06 | Dividend Yield | — |
| Payout | 0.00% | Employees | 46 | IPO | — |
| P/E | — | Forward P/E | 96.38 | PEG | — |
| P/S | 4.27 | P/B | 1.89 | P/C | — |
| EV/EBITDA | -178.23 | EV/Sales | 210.07 | Quick Ratio | 5.71 |
| Current Ratio | 5.85 | Debt/Eq | 44.04 | LT Debt/Eq | — |
| EPS (ttm) | -1.00 | EPS next Y | 0.04 | EPS Growth | — |
| Revenue Growth | -100.00% | Earnings | 2026-03-05 09:00 | ROA | -28.23% |
| ROE | -100.17% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -122.66% | Profit Margin | -102.38% | Shs Outstand | 8.34M |
| Shs Float | 283.97M | Short Float | 0.77% | Short Ratio | 1.02 |
| Short Interest | — | 52W High | 12.15 | 52W Low | 1.20 |
| Beta | 0.32 | Avg Volume | 62.94K | Volume | 3.60K |
| Target Price | $11.25 | Recom | Strong_buy | Prev Close | $3.83 |
| Price | $3.85 | Change | 0.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.25
Mean price target
2. Current target
$3.78
Latest analyst target
3. DCF / Fair value
$-9.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.78
Low
$9.00
High
$16.00
Mean
$11.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-10 | init | Jones Trading | — → Buy | $10 |
| 2026-03-09 | main | Lake Street | Buy → Buy | $9 |
| 2026-03-09 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-10-30 | init | Edward Jones | — → Buy | $10 |
| 2025-10-20 | main | Lake Street | Buy → Buy | $11 |
| 2025-10-20 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-09-25 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-04-02 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-20 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2025-02-04 | main | Lake Street | Buy → Buy | $6 |
| 2025-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-11-01 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-09-26 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-09-20 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2024-04-02 | up | Ladenburg Thalmann | Neutral → Buy | $8 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
- AI cancer vaccines for melanoma and deadly brain tumors on AACR stage - Stock Titan ue, 17 Mar 2026 20
- Evaxion (NASDAQ: EVAX) to share EVX-01 and glioblastoma data at AACR - Stock Titan ue, 17 Mar 2026 20
- Evaxion A/S - American Depositary Share (NQ: EVAX - The Chronicle-Journal Sun, 15 Mar 2026 10
- Evaxion Biotech stock holds Buy rating at H.C. Wainwright after ASH data - Investing.com Wed, 10 Dec 2025 08
- Lake Street Raises Evaxion (EVAX) PT to $11 Following Positive Two-Year EVX-01 Melanoma Data - Yahoo Finance Sun, 26 Oct 2025 07
- Evaxion Delays 2025 Annual Report Filing Due to Technical Issues - TipRanks hu, 05 Mar 2026 08
- EVAX Technical Analysis & Stock Price Forecast - Intellectia AI Sun, 08 Mar 2026 01
- Jones Trading initiates coverage of Evaxion A (EVAX) with buy recommendation - MSN Mon, 16 Mar 2026 01
- Evaxion Biotech stock soars after MSD licenses its vaccine candidate - Investing.com hu, 25 Sep 2025 07
- Technical glitch pushes Evaxion’s 2025 annual report call to Friday - Stock Titan hu, 05 Mar 2026 08
- Evaxion Biotech Issues Over 9 Million New Warrants to Insiders in February 2026 - TipRanks Fri, 27 Feb 2026 08
- AI vaccine firm Evaxion to detail 2025 finances and plans - Stock Titan Mon, 02 Mar 2026 08
- AI vaccine firm Evaxion lands MSD deal worth up to $592 million - Stock Titan hu, 05 Mar 2026 08
- Minor delay to Evaxion (NASDAQ: EVAX) 2025 annual report and call - Stock Titan hu, 05 Mar 2026 13
- AI-driven vaccine firm Evaxion targets autoimmune diseases next globally - Stock Titan ue, 13 Jan 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -144.61K | 283.49K | 1.00K | 84.32K |
| TaxRateForCalcs | 0.11 | 0.07 | 0.04 | 0.04 |
| NormalizedEBITDA | -5.75M | -13.87M | -21.43M | -24.68M |
| TotalUnusualItems | -1.37M | 4.08M | 25.00K | 2.11M |
| TotalUnusualItemsExcludingGoodwill | -1.37M | 4.08M | 25.00K | 2.11M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.71M | -10.57M | -22.12M | -23.17M |
| ReconciledDepreciation | 615.00K | 607.00K | 615.00K | 571.00K |
| EBITDA | -7.12M | -9.79M | -21.40M | -22.57M |
| EBIT | -7.74M | -10.39M | -22.02M | -23.14M |
| NetInterestIncome | 1.99M | -708.00K | -743.00K | -785.00K |
| InterestExpense | 876.00K | 962.00K | 897.00K | 798.00K |
| InterestIncome | 299.00K | 254.00K | 154.00K | 13.00K |
| NormalizedIncome | -6.48M | -14.37M | -22.15M | -25.19M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.71M | -10.57M | -22.12M | -23.17M |
| TotalExpenses | 16.76M | 18.08M | 22.27M | 25.26M |
| TotalOperatingIncomeAsReported | -9.23M | -14.73M | -22.20M | -25.26M |
| DilutedAverageShares | 1.07M | 546.72K | 472.77K | 389.86K |
| BasicAverageShares | 1.07M | 546.72K | 472.77K | 389.86K |
| DilutedEPS | -10.00 | -40.50 | -49.00 | -63.00 |
| BasicEPS | -10.00 | -40.50 | -49.00 | -63.00 |
| DilutedNIAvailtoComStockholders | -7.71M | -10.57M | -22.12M | -23.17M |
| NetIncomeCommonStockholders | -7.71M | -10.57M | -22.12M | -23.17M |
| NetIncome | -7.71M | -10.57M | -22.12M | -23.17M |
| NetIncomeIncludingNoncontrollingInterests | -7.71M | -10.57M | -22.12M | -23.17M |
| NetIncomeContinuousOperations | -7.71M | -10.57M | -22.12M | -23.17M |
| TaxProvision | -908.00K | -788.00K | -790.00K | -772.00K |
| PretaxIncome | -8.62M | -11.36M | -22.91M | -23.94M |
| OtherIncomeExpense | -1.37M | 4.08M | 25.00K | 2.11M |
| GainOnSaleOfSecurity | -1.37M | 4.08M | 25.00K | 2.11M |
| NetNonOperatingInterestIncomeExpense | 1.99M | -708.00K | -743.00K | -785.00K |
| TotalOtherFinanceCost | -2.57M | |||
| InterestExpenseNonOperating | 876.00K | 962.00K | 897.00K | 798.00K |
| InterestIncomeNonOperating | 299.00K | 254.00K | 154.00K | 13.00K |
| OperatingIncome | -9.23M | -14.73M | -22.20M | -25.26M |
| OperatingExpense | 16.76M | 18.08M | 22.27M | 25.26M |
| DepreciationAmortizationDepletionIncomeStatement | 301.00K | 302.00K | 275.00K | 144.00K |
| DepreciationAndAmortizationInIncomeStatement | 301.00K | 302.00K | 275.00K | 144.00K |
| DepreciationIncomeStatement | 301.00K | 302.00K | 275.00K | 144.00K |
| ResearchAndDevelopment | 9.97M | 10.46M | 11.92M | 17.06M |
| SellingGeneralAndAdministration | 6.49M | 7.32M | 10.08M | 8.06M |
| GeneralAndAdministrativeExpense | 6.49M | 7.32M | 10.08M | 8.06M |
| OtherGandA | 3.81M | 4.73M | 6.95M | 5.90M |
| SalariesAndWages | 2.67M | 2.59M | 3.13M | 2.17M |
| TotalRevenue | 7.53M | 3.34M | 73.00K | 0.00 |
| OperatingRevenue | 7.53M | 3.34M | 73.00K | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 417.01M | 70.13M | 37.90M | 24.14M |
| ShareIssued | 417.01M | 70.13M | 37.90M | 24.14M |
| NetDebt | 2.21M | 4.46M | ||
| TotalDebt | 7.50M | 10.10M | 10.87M | 10.26M |
| TangibleBookValue | 17.04M | -1.65M | -4.73M | 8.30M |
| InvestedCapital | 22.58M | 6.51M | 3.92M | 16.30M |
| WorkingCapital | 20.64M | 4.40M | 1.27M | 13.22M |
| NetTangibleAssets | 17.04M | -1.65M | -4.73M | 8.30M |
| CapitalLeaseObligations | 1.97M | 1.93M | 2.22M | 2.25M |
| CommonStockEquity | 17.04M | -1.65M | -4.73M | 8.30M |
| TotalCapitalization | 22.39M | 6.36M | 3.76M | 16.17M |
| TotalEquityGrossMinorityInterest | 17.04M | -1.65M | -4.73M | 8.30M |
| StockholdersEquity | 17.04M | -1.65M | -4.73M | 8.30M |
| OtherEquityInterest | 9.99M | 14.02M | 13.66M | 13.19M |
| GainsLossesNotAffectingRetainedEarnings | -3.23M | -3.60M | -3.77M | -3.65M |
| OtherEquityAdjustments | 79.11M | |||
| ForeignCurrencyTranslationAdjustments | -3.23M | -3.60M | -3.77M | -3.65M |
| RetainedEarnings | -126.24M | -118.54M | -107.97M | -85.84M |
| AdditionalPaidInCapital | 120.73M | 95.94M | 87.45M | 80.73M |
| CapitalStock | 15.79M | 10.52M | 5.90M | 3.89M |
| CommonStock | 15.79M | 10.52M | 5.90M | 3.89M |
| TotalLiabilitiesNetMinorityInterest | 11.37M | 14.14M | 17.62M | 13.72M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.11M | 9.77M | 10.53M | 9.96M |
| OtherNonCurrentLiabilities | 10.00K | |||
| LongTermDebtAndCapitalLeaseObligation | 6.95M | 9.63M | 10.38M | 9.82M |
| LongTermCapitalLeaseObligation | 1.61M | 1.62M | 1.90M | 1.95M |
| LongTermDebt | 5.35M | 8.01M | 8.49M | 7.86M |
| LongTermProvisions | 158.00K | 141.00K | 149.00K | 144.00K |
| CurrentLiabilities | 4.26M | 4.37M | 7.08M | 3.76M |
| OtherCurrentLiabilities | 416.00K | 67.00K | 3.02M | 885.00K |
| CurrentDebtAndCapitalLeaseObligation | 550.00K | 473.00K | 485.00K | 439.00K |
| CurrentCapitalLeaseObligation | 360.00K | 314.00K | 326.00K | 303.00K |
| CurrentDebt | 190.00K | 159.00K | 159.00K | 136.00K |
| OtherCurrentBorrowings | 190.00K | 159.00K | 159.00K | 136.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.10M | 860.00K | 894.00K | 353.00K |
| PayablesAndAccruedExpenses | 2.19M | 2.97M | 2.69M | 2.08M |
| Payables | 2.19M | 2.97M | 2.69M | 2.08M |
| OtherPayable | 312.00K | 46.00K | ||
| AccountsPayable | 2.19M | 2.97M | 2.69M | 2.08M |
| TotalAssets | 28.41M | 12.48M | 12.89M | 22.02M |
| TotalNonCurrentAssets | 3.51M | 3.72M | 4.54M | 5.04M |
| NonCurrentPrepaidAssets | 185.00K | 162.00K | 167.00K | 156.00K |
| NonCurrentDeferredAssets | 0.00 | |||
| NonCurrentDeferredTaxesAssets | 0.00 | |||
| NonCurrentAccountsReceivable | 44.00K | 29.00K | 209.00K | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 93.00K | ||
| NetPPE | 3.32M | 3.51M | 4.34M | 4.67M |
| AccumulatedDepreciation | -2.20M | -1.53M | -1.17M | -721.00K |
| GrossPPE | 5.52M | 5.05M | 5.51M | 5.40M |
| Leases | 1.13M | 1.16M | 1.39M | 1.44M |
| OtherProperties | 4.39M | 3.89M | 4.12M | 3.96M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 24.90M | 8.77M | 8.35M | 16.98M |
| CurrentDeferredAssets | 0.00 | |||
| RestrictedCash | 900.00K | 1.40M | ||
| PrepaidAssets | 616.00K | 955.00K | 1.69M | 2.49M |
| Receivables | 1.05M | 1.86M | 1.07M | 1.31M |
| OtherReceivables | 102.00K | 117.00K | 231.00K | 676.00K |
| TaxesReceivable | 1.05M | 1.76M | 958.00K | 1.08M |
| CashCashEquivalentsAndShortTermInvestments | 23.23M | 5.95M | 4.18M | 13.18M |
| CashAndCashEquivalents | 23.23M | 5.95M | 4.18M | 13.18M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.64M | -12.94M | -17.78M | -26.07M |
| RepaymentOfDebt | -751.00K | -1.14M | -697.00K | -424.00K |
| IssuanceOfDebt | 0.00 | 0.00 | 65.00K | 7.85M |
| IssuanceOfCapitalStock | 23.16M | 14.21M | 11.32M | 428.00K |
| CapitalExpenditure | -11.00K | -87.00K | -292.00K | -1.36M |
| EndCashPosition | 23.23M | 5.95M | 5.58M | 13.18M |
| BeginningCashPosition | 5.95M | 5.58M | 13.18M | 32.17M |
| EffectOfExchangeRateChanges | 1.51M | 183.00K | -508.00K | -793.00K |
| ChangesInCash | 15.77M | 186.00K | -7.09M | -18.19M |
| FinancingCashFlow | 22.41M | 13.13M | 10.69M | 7.85M |
| CashFlowFromContinuingFinancingActivities | 22.41M | 13.13M | 10.69M | 7.85M |
| NetOtherFinancingCharges | 59.00K | -432.00K | -3.76M | |
| ProceedsFromStockOptionExercised | 0.00 | 2.59M | 0.00 | 0.00 |
| NetCommonStockIssuance | 23.16M | 14.21M | 11.32M | 428.00K |
| CommonStockIssuance | 23.16M | 14.21M | 11.32M | 428.00K |
| NetIssuancePaymentsOfDebt | -751.00K | -1.14M | -632.00K | 7.42M |
| NetLongTermDebtIssuance | -751.00K | -1.14M | -632.00K | 7.42M |
| LongTermDebtPayments | -751.00K | -1.14M | -697.00K | -424.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | 65.00K | 7.85M |
| InvestingCashFlow | -14.00K | -3.00K | -93.00K | -268.00K |
| CashFlowFromContinuingInvestingActivities | -14.00K | -3.00K | -93.00K | -268.00K |
| NetInvestmentPurchaseAndSale | -3.00K | -3.00K | -6.00K | 24.00K |
| SaleOfInvestment | 24.00K | 30.00K | ||
| PurchaseOfInvestment | -3.00K | -3.00K | -6.00K | |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | 0.00 | -60.00K |
| PurchaseOfIntangibles | 0.00 | 0.00 | 0.00 | -60.00K |
| NetPPEPurchaseAndSale | -11.00K | 0.00 | -87.00K | -292.00K |
| SaleOfPPE | 24.00K | 30.00K | ||
| PurchaseOfPPE | -11.00K | 0.00 | -87.00K | -292.00K |
| OperatingCashFlow | -6.62M | -12.94M | -17.69M | -25.77M |
| CashFlowFromContinuingOperatingActivities | -6.62M | -12.94M | -17.69M | -25.77M |
| TaxesRefundPaid | 1.63M | 0.00 | 1.60M | 754.00K |
| InterestReceivedCFO | 299.00K | 254.00K | 154.00K | 13.00K |
| InterestPaidCFO | -107.00K | -56.00K | -65.00K | -172.00K |
| ChangeInWorkingCapital | -137.00K | 520.00K | 1.56M | -2.88M |
| ChangeInOtherWorkingCapital | -185.00K | 13.00K | -261.00K | |
| ChangeInPayablesAndAccruedExpense | -536.00K | -62.00K | 762.00K | -1.39M |
| ChangeInPayable | -536.00K | -62.00K | 762.00K | -1.39M |
| ChangeInAccountPayable | -536.00K | -62.00K | 762.00K | -599.00K |
| ChangeInPrepaidAssets | 406.00K | 736.00K | 802.00K | |
| ChangeInReceivables | 178.00K | -167.00K | 259.00K | -1.49M |
| OtherNonCashItems | -619.00K | -3.24M | 1.08M | -530.00K |
| StockBasedCompensation | 307.00K | 357.00K | 479.00K | 942.00K |
| AssetImpairmentCharge | 0.00 | 0.00 | 87.00K | 0.00 |
| DeferredTax | -908.00K | -813.00K | -984.00K | -998.00K |
| DeferredIncomeTax | -908.00K | -813.00K | -984.00K | -998.00K |
| DepreciationAmortizationDepletion | 615.00K | 607.00K | 615.00K | 571.00K |
| DepreciationAndAmortization | 615.00K | 607.00K | 615.00K | 571.00K |
| Depreciation | 615.00K | 607.00K | 615.00K | 571.00K |
| OperatingGainsLosses | -3.88M | -282.00K | -395.00K | |
| GainLossOnInvestmentSecurities | -3.88M | -282.00K | -395.00K | |
| NetIncomeFromContinuingOperations | -7.71M | -10.57M | -22.12M | -23.17M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for EVAX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|